DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Uroxatral (Alfuzosin Hydrochloride) - Indications and Dosage



UROXATRAL (alfuzosin HCl extended-release tablets) is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension.


The recommended dosage is one 10 mg UROXATRAL (alfuzosin HCl extended-release tablets) tablet daily to be taken immediately after the same meal each day. The tablets should not be chewed or crushed.


UROXATRAL (alfuzosin HCl extended-release tablets) 10 mg is available as a round, three-layer tablet: one white layer between two yellow layers, debossed with X10. UROXATRAL is supplied as follows:

PackageNDC Number
Bottles of 300024-4200-30
Bottles of 1000024-4200-10
Hospital Unit Dose (blister packs containing 10 cards of 10 tablets each)0024-4200-20

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Protect from light and moisture.

Keep UROXATRAL out of reach of children.

sanofi-aventis U.S. LLC
Bridgewater, NJ 08807

UROXATRAL® is a registered trademark of sanofi-aventis U.S. LLC.

Revised August 2008

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015